Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) EBIT Margin (2016 - 2025)

Haemonetics has reported EBIT Margin over the past 17 years, most recently at 19.88% for Q4 2025.

  • Quarterly results put EBIT Margin at 19.88% for Q4 2025, up 295.0% from a year ago — trailing twelve months through Dec 2025 was 19.05% (up 591.0% YoY), and the annual figure for FY2025 was 16.3%, up 370.0%.
  • EBIT Margin for Q4 2025 was 19.88% at Haemonetics, up from 17.87% in the prior quarter.
  • Over the last five years, EBIT Margin for HAE hit a ceiling of 21.58% in Q1 2025 and a floor of 9.41% in Q2 2021.
  • Median EBIT Margin over the past 5 years was 13.7% (2022), compared with a mean of 12.31%.
  • Biggest five-year swings in EBIT Margin: crashed -2031bps in 2021 and later soared 1665bps in 2022.
  • Haemonetics' EBIT Margin stood at 10.22% in 2021, then skyrocketed by 39bps to 14.18% in 2022, then fell by -4bps to 13.67% in 2023, then increased by 24bps to 16.94% in 2024, then increased by 17bps to 19.88% in 2025.
  • The last three reported values for EBIT Margin were 19.88% (Q4 2025), 17.87% (Q3 2025), and 16.76% (Q2 2025) per Business Quant data.